Analysts Offer Insights on Healthcare Companies: Cytori Therapeutics Inc (NASDAQ: CYTX), SCYNEXIS (NASDAQ: SCYX) and Idera (NASDAQ: IDRA)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytori Therapeutics Inc (NASDAQ:CYTX), SCYNEXIS (NASDAQ:SCYX) and Idera (NASDAQ:IDRA) with bullish sentiments.

Cytori Therapeutics Inc (CYTX)

H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Cytori Therapeutics Inc today and set a price target of $6. The company’s shares closed yesterday at $1.42, close to its 52-week low of $1.40.

Kolbert commented:

“We have adjusted our valuation to reflect the reverse stock split and the proposed offering as well as our capital raise assumptions going forward. We have made no changes to our other model assumptions. Our model forecasts feed into our valuation metrics, of free cash flow to the firm (FCFF), discounted EPS (dEPS) and sum-of-the-parts (SOP) models. We use a 30% discount rate, which is typical for emerging growth companies. The models are equal weighted and averaged to derive our price target which now goes to $6.00 from $4.00 as a result of the change to the out year assumed share count.”

According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.7% and a 38.4% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Can-Fite BioPharma, and Keryx Biopharma.

Currently, the analyst consensus on Cytori Therapeutics Inc is a Strong Buy with an average price target of $5.

See today’s analyst top recommended stocks >>

SCYNEXIS (SCYX)

In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on SCYNEXIS, with a price target of $5. The company’s shares closed yesterday at $1.65.

Livnat commented:

“Valuation and risks. Our $5 target is based on a probability-adjusted DCF. Our estimates include oral’078 for VVC launching in 2021 with peak sales >$300M, and IV+oral ‘078 for IC launching in 2023 with $200M peak. We do not include any other antifungal indications or ex-US partnerships. We project profitability in 2023, and our DCF reflects a 16% WACC discount rate and 2% terminal growth beyond 2028 to account for potential additional indications, at least 10 years ‘078 statutory exclusivity (5-years NCE plus 5-years QIDP), and composition patent protection up to 2035.”

According to TipRanks.com, Livnat has 0 stars on 0-5 star ranking scale with an average return of -4.4% and a 45.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on SCYNEXIS is a Strong Buy with an average price target of $6, which is a 263.6% upside from current levels. In a report issued on June 27, Maxim Group also initiated coverage with a Buy rating on the stock with a $6 price target.

.

Idera (IDRA)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Idera, with a price target of $4. The company’s shares closed yesterday at $1.37, close to its 52-week low of $1.12.

Ramakanth noted:

“We are maintaining our Buy rating of IDRA and our 12-month price target of $4.00. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues through 2027 assuming a 12% discount rate and 3% terminal growth rate. We derive an rNPV of $985M and upon inclusion of $113M in cash and cash equivalents to arrive at a 12-month price target of $4.21 per diluted share, which we round to $4.00. (1) clinical; (2) partnership; (3) commercial; (4) financial; and (5) intellectual property.”

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 8.4% and a 40.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Idera with a $4 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.